Recent News

By Category: Research

Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax…

(Press release) EBS today announced the initiation of a pivotal immunogenicity and safety study to evaluate a three-dose vaccination schedule of BioThrax(R) (Anthrax Vaccine Adsorbed) for administration to individuals exposed to anthrax. Through this pivotal, licensure-enabling clinical study, the company seeks to obtain a post-exposure prophylaxis (PEP) indication for BioThrax. Approval of the PEP indication Read More »

November 18, 2011
| Filed under North America, Biotechnology, Countermeasures, Public Health, and Research
Share

PharmAthene to Present at the 2011 Chemical and Biological Defense Science and …

(Sacramento Bee) PharmAthene, Inc. announced today that data from its rPA anthrax vaccine and chemical nerve agent bioscavenger programs will be presented at the 2011 Chemical and Biological Defense Science and Technology …

November 17, 2011
| Filed under North America, Biotechnology, Countermeasures, and Research
Share

Alarming pattern of antibiotic use in the southeastern United States

(EurekAlert!) New research suggests a pattern of outpatient antibiotic overuse in parts of the United States — particularly in the Southeast — a problem that could accelerate the rate at which these powerful drugs are rendered useless, according to Extending the Cure, a project of the Center for Disease Dynamics, Economics & Policy.

November 17, 2011
| Filed under North America, Public Health, and Research
Share

Opinion: The Dark Side of Science

(The Scientist) Within the burgeoning field of synthetic biology, teams of biologists and engineers are making great strides in understanding the cell and its functioning. (See The Scientist’s recent feature on the topic.) However, there is more that should be discussed than the triumphs. There are also the dark purposes to which science (and synthetic Read More »

November 17, 2011
| Filed under North America, Biotechnology, and Research
Share

Smallpox vaccine doubles liver cancer survival time

(New Scientist) Smallpox vaccine has doubled the survival time of people with advanced liver cancer. The vaccine that eradicated smallpox consists of a live virus, Vaccinia, with a surprising taste for tumours. It prefers to infect cancer cells because they turn off …